Question follow-through · 69134
Radiotherapy
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of establishing a national radiotherapy advisory group.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 18 Jul 2025
- Target answer date
- 22 Jul 2025
- Answer
- 28 Jul 2025 · 10 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Prostate Cancer: Hormone Treatments · 1 Sept 2025
- Clinical Priorities Advisory Group · 11 Sept 2025
- Medical Treatments · 10 Oct 2025
- Rare Cancers: Diagnosis · 14 Oct 2025
- Rare Cancers: Medical Treatments · 14 Oct 2025
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
18 Jul 2025
Question tabled
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of establishing a national radiotherapy advisory group.
22 Jul 2025
Target answer date
Date supplied by the official written-questions record.
28 Jul 2025
Answer published
The Government recognises radiotherapy as a crucial part of cancer treatment, which is why we have invested £70 million in 28 new radiotherapy machines to ensure the most advanced radiotherapy treatment is available to patients when they need it.There are...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Prostate Cancer: Hormone Treatments
1 Sept 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2025 to Question 64681 on Prostate Cancer: Hormone Treatments, for what reason recurrent headroom in revenue budgets is considered a barrier to implementing the abi
Clinical Priorities Advisory Group
11 Sept 2025 · To ask the Secretary of State for Health and Social Care, whether the Clinical Priorities Advisory Group has a budget to approve new treatments.
Medical Treatments
10 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether there is a facility for the NHS to approve treatments without external payment for assessment by the National Institute for Health and Care Excellence.
Rare Cancers: Diagnosis
14 Oct 2025 · To ask the Secretary of State for Health and Social Care, how the full roll-out of the non-specific symptom pathways is being measured; and how their development has included the less survivable cancers.
Rare Cancers: Medical Treatments
14 Oct 2025 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of minimally invasive therapies for the less survivable cancers.
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of men in England with newly diagnosed high-risk, non-metastatic prostate cancer who would be eligible for abiraterone under the eligibility crit
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, if he will make an estimate of the potential impact of prescribing abiraterone in England using the eligibility criteria used in (a) Scotland and (b) Wales on the number of premature deaths from hi
Prostate Cancer: Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, if he will make an estimate of the (a) cost per patient, (b) number of eligible patients, (c) net cost, (d) incremental quality-adjusted life years gained and (e) incremental cost-effectiveness rat
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether NHS England has approved any drugs with a higher incremental cost-effectiveness ratio than abiraterone for high-risk, non-metastatic prostate cancer in the last five years.
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, what information his Department holds on the estimate made by (a) NHS England, (b) NHS Wales and (c) NHS Scotland of the incremental cost-effectiveness ratio for abiraterone in high-risk, non-metas
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, for what reason NHS England has not approved abiraterone for use in high-risk, non-metastatic prostate cancer.
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether the NICE guidance on abiraterone produced in 2021 was based on abiraterone's cost in generic form.